Skip to main content
Oncology

HER2

A protein that's overexpressed in some breast and gastric cancers, drives targeted therapy choice.

HER2 (human epidermal growth factor receptor 2) status is tested on breast and gastric cancer specimens. HER2-positive cancers respond to targeted therapies (trastuzumab, pertuzumab, T-DM1).

What this means for you: confirm HER2 testing has been done on your tumor. Without it, you may receive inferior therapy.

General information, not medical advice

What a term means for you depends on your own reports. Ask your treating doctor, or send your reports for a free review.

More Oncology terms

Want this explained for your case?

Send your reports once. A doctor reviews them and you get written quotes from up to 3 hospitals, free.

Get free quotes Back to the glossary
How this page is made

Methodology and editorial standards

Glossary entries are written by the Medcasts editorial team in plain language and checked against current clinical and regulatory sources.

  1. Hospital data. Accreditation, licences and facilities are checked against public registries (JCI, NABH, health-ministry licence lists) and hospital documents, and rechecked regularly.
  2. Doctor credentials. Qualifications and specialty come from the doctor's hospital profile and national medical council registers.
  3. Prices. Price ranges come from written hospital quotes and packages, not advertised rates.
  4. Clinical text. Written by our editorial team and checked against current published guidelines before it goes live.
  5. Independence. Hospitals cannot pay to change their position on our pages.